Get the Stockscreener App
6.65
2.49%
0.1614
After Hours:
6.65
Kala Bio Inc stock is traded at $6.65, with a volume of 83,946.
It is up +2.49% in the last 24 hours and down -2.21% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$6.4886
Open:
$6.45
24h Volume:
83,946
Relative Volume:
3.79
Market Cap:
$30.70M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-95.00
EPS:
-0.07
Net Cash Flow:
$-32.63M
1W Performance:
+3.42%
1M Performance:
-2.21%
6M Performance:
+2.13%
1Y Performance:
+10.83%
1-Day Range:
$6.25
$6.95
1-Week Range:
$6.10
$7.03
52-Week Range:
$4.21
$10.97
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
6.65 | 30.70M | 5.75M | -38.96M | -32.63M | -0.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
FTC Solar Announces Reverse Stock Split - The Manila Times
KALA BIO to Present at Piper Sandler Healthcare Conference, Showcasing Eye Disease Pipeline | KALA Stock News - StockTitan
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire Inc.
2024 Pharmaceutical Executive APEX Award Winners - Pharmaceutical Executive
Kala Pharmaceuticals Announces IND Submission of its MPP-Formulated Loteprednol Etonbonate (LE-MPP) for Post-Cataract Surgery - Marketscreener.com
Kala Pharmaceuticals retains stock target with Buy rating on trial progress - Investing.com India
60 Degrees Pharmaceuticals’ (SXTP) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Walt Disney (NYSE:DIS) Price Target Raised to $130.00 - Defense World
KALA BIO’s (KALA) Buy Rating Reaffirmed at HC Wainwright - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kala Bio Inc - GuruFocus.com
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
KALA BIO: Q3 Earnings Snapshot - mySA
KALA BIO Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
KALA BIO Reports $49.2M Cash Position, Advances Phase 2b PCED Trial Despite Wider Losses | KALA Stock News - StockTitan
Super Micro slumps as weak forecast, annual report uncertainty fuel investor angst - AOL
Standard Life Private Equity Trust (LON:SLPE) Trading Down 1.5% – Here’s Why - Defense World
Travis Kalanick | Biography, Uber, & Facts - Britannica
Persistent Corneal Epithelial Defects Pipeline 2024: Clinical - openPR
Persistent Epithelial Defect Market Size is Set for Rapid Growth - openPR
Sunrun (NASDAQ:RUN) Trading Down 5.8% on Insider Selling - Defense World
MPTI Stock Trades Near 52-Week High: Is It Still Worth Buying? - MSN
Here's What Makes Cabot Stock a Solid Choice Right Now - MSN
Here's Why Welltower Stock is an Apt Portfolio Pick for Now - MSN
Broadcom Stock Hits Buy Point On Product News Ahead Of Major Conference - MSN
KALA BIO (KALA) Moves to Strong Buy: Rationale Behind the Upgrade - Yahoo Finance
Dynatrace Shows Improved Relative Strength; Still Shy Of Benchmark - MSN
Brookdale Bets Big With $610M Acquisitions Amid Debt Refinancing - MSN
Toast, Inc. (TOST) is Attracting Investor Attention: Here is What You Should Know - MSN
Here's Why Freeport-McMoRan Stock Soared in September - AOL
Oppenheimer Initiates Coverage of Euronet Worldwide (EEFT) with Outperform Recommendation - MSN
Transparency-One’s Kala Hanson Named Recipient of 2024 Women in Supply Chain Award - Yahoo Finance
AAM Names John A. Murphy as CEO - Pharmaceutical Executive
KALA BIO director resigns from board and committees By Investing.com - Investing.com Australia
KALA BIO director resigns from board and committees - Investing.com
Kala Pharmaceuticals Board Member Mark Blumenkranz Resigns - TipRanks
Kaival Brands’ (KAVL) Stock Surges After Merger Announcement with Delta Corp. - TipRanks
(KALA) Long Term Investment Analysis - Stock Traders Daily
Glazer Capital LLC Trims Holdings in Kairous Acquisition Corp. Limited (NASDAQ:KACL) - Defense World
Kaival Brands Innovations Group Inc. (NASDAQ:KAVL) Stock Makes a Big Move: But Why? - DRP Journal
Celebrities pour in appreciation for Vikky Varun's Kalapatthar - Cinema Express
Luminar Technologies Surged Today on Potential Trade Protections - AOL
Market Movers Monday: KAVL, PRSO, TGL, PNPNF, NVVE Surge on Breaking Developments - openPR
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
Kaival Brands Shares More Than Double on Delta Corp Holdings Merger - MarketWatch
What's Going On With Kaival Brands Stock Monday? - Benzinga
Kaival Brands Announces Strategic Merger with Delta Corp - TipRanks
Delta Corp Holdings Limited, a Fast Growing Asset-Light Logistics Company Enters into a Definitive Merger and Share Exchange Agreement with Kaival Brands Innovations Group, Inc. - StockTitan
Kayne Anderson Rudnick Investment Management LLC Purchases 15,512 Shares of Kadant Inc. (NYSE:KAI) - Defense World
ProShares Short S&P500 (NYSEARCA:SH) Hits New 12-Month Low at $11.02 - Defense World
Orange (NYSE:ORAN) Trading Down 1.7% - Defense World
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Jun 26 '24 |
Sale |
4.75 |
5,158 |
24,500 |
59,728 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Jun 26 '24 |
Sale |
4.75 |
4,163 |
19,774 |
60,187 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
Jun 26 '24 |
Sale |
4.75 |
15,168 |
72,048 |
263,755 |
| Brazzell Romulus K | SEE REMARKS |
Jun 26 '24 |
Sale |
4.75 |
5,489 |
26,073 |
83,982 |
| Bazemore Todd | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,093 |
12,746 |
87,693 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
May 31 '24 |
Sale |
6.09 |
231 |
1,407 |
64,886 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
May 31 '24 |
Sale |
6.09 |
1,786 |
10,877 |
64,350 |
| Brazzell Romulus K | SEE REMARKS |
May 31 '24 |
Sale |
6.09 |
2,002 |
12,192 |
89,471 |
| Iwicki Mark T | CHIEF EXECUTIVE OFFICER |
May 31 '24 |
Sale |
6.09 |
7,392 |
45,017 |
278,923 |
| Trachtenberg Eric | SEE REMARKS |
Jan 04 '24 |
Sale |
6.74 |
1,227 |
8,270 |
68,066 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):